With more than 2,700 employees and 36 subsidiaries worldwide, Merz has evolved as a leading provider of aesthetics and special neurology. Privately held for more than 100 years, the company is distinguished by its innovative in-house R&D, solid financial strength and the right strategy for long-term growth.

Merz also develops and produces agents and therapies for neurology and medical dermatology. OTC medicines, dietary supplements and skincare products round off the companyÍs highly attractive portfolio. In fiscal year 2014/15 the Merz Pharma Group generated revenue of EUR 1,157.0 million.